# Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

> **NCT06854445** · PHASE2 · RECRUITING · sponsor: **Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.** · enrollment: 55 (estimated)

## Conditions studied

- Diffuse Large Cell B-lymphoma

## Interventions

- **DRUG:** TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection

## Key facts

- **NCT ID:** NCT06854445
- **Lead sponsor:** Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2025-10
- **Final completion:** 2028-02
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06854445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06854445, "Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06854445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*